1,108 research outputs found
On topological defect formation in the process of symmetry breaking phase transitions
By resorting to some results in quantum field theories with spontaneous
breakdown of symmetry we show that an explanation based on microscopic dynamics
can be given of the fact that topological defect formation is observed during
the process of non-equilibrium phase transitions characterized by a non-zero
order parameter. We show that the Nambu-Goldstone particle acquires an
effective non-zero mass due to the boundary (finite volume) effects and this is
related with the size of the defect. We also relate such volume effect with
temperature effect.Comment: 12 pages, no figure
Recommended from our members
Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.
Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs), however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1-DRD5, ADRA2A, SLC6A3, SLC6A4, MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively homogeneous sample, significant differences by DRD1 (P=0.006), ADRA2A (P<0.02), COMT (P<0.04), DRD3 (P<0.05), DRD4 (P<0.05), SLC6A3 (P<0.05) and SLC6A4 (P<0.05) genotypes were found for responders versus non-responders. Variants in DRD2 (P<0.001) and DRD3 (P<0.04) were associated with tolerability in the 14 subjects who discontinued the trial. For this first MPH pharmacogenetic study in children with ASD, multiple monoaminergic gene variants may help explain individual differences in MPH's efficacy and tolerability
On flavor conservation in weak interaction decays involving mixed neutrinos
In the context of quantum field theory (QFT), we compute the amplitudes of
weak interaction processes such as and by using different representations of
flavor states for mixed neutrinos. Analyzing the short time limit of the above
amplitudes, we find that the neutrino states defined in QFT as eigenstates of
the flavor charges lead to results consistent with lepton charge conservation.
On the contrary, the Pontecorvo flavor states produce a violation of lepton
charge in the vertex, which is in contrast with what expected at tree level in
the Standard Model.Comment: 15 page
Child and adolescent mental health service provision and research during the Covid-19 pandemic: Challenges, opportunities, and a call for submissions
Obsessive–compulsive symptoms in young women affected with anorexia nervosa, and their relationship with personality, psychopathology, and attachment style
Recent developments and strategies in pediatric pharmacology research in the USA
Research in pediatric pharmacology has undergone major changes in the last ten years, with an expansion in both publicly and privately funded activities. A number of pharmacokinetics studies and multi-site controlled efficacy trials have been conducted, so that treatment of children and adolescents can now be better informed and evidence-based. Regulatory financial incentives to industry in return for studies on drugs still covered by patent exclusivity have resulted in a substantial increase in pediatric research funded by pharmaceutical companies. In parallel, public funding has supported research on off-patent medications and other clinical important aspects of treatment, such as comparisons between active treatments, including non-pharmacological interventions. With greater interest by industry in pediatric research, the role of government funding agencies has been redefined to avoid duplication and ensure better integration of efforts and utilization of resources. The present review discusses some of the recent developments in pediatric pharmacology with focus on psychiatric medications
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.
Second-generation antipsychotic exposure, in both children and adults, carries significant risk for excessive weight gain that varies widely across individuals. We queried common variation in key energy balance genes (FTO, MC4R, LEP, CNR1, FAAH) for their association with weight gain during the initial 8 weeks in the two NIMH Research Units on Pediatric Psychopharmacology Autism Network trials (N=225) of risperidone for treatment of irritability in children/adolescents aged 4-17 years with autism spectrum disorders. Variants in the cannabinoid receptor (CNR)-1 promoter (P=1.0 Ă— 10(-6)), CNR1 (P=9.6 Ă— 10(-5)) and the leptin (LEP) promoter (P=1.4 Ă— 10(-4)) conferred robust-independent risks for weight gain. A model combining these three variants was highly significant (P=1.3 Ă— 10(-9)) with a 0.85 effect size between lowest and highest risk groups. All results survived correction for multiple testing and were not dependent on dose, plasma level or ethnicity. We found no evidence for association with a reported functional variant in the endocannabinoid metabolic enzyme, fatty acid amide hydrolase, whereas body mass index-associated single-nucleotide polymorphisms in FTO and MC4R showed only trend associations. These data suggest a substantial genetic contribution of common variants in energy balance regulatory genes to individual antipsychotic-associated weight gain in children and adolescents, which supersedes findings from prior adult studies. The effects are robust enough to be detected after only 8 weeks and are more prominent in this largely treatment naive population. This study highlights compelling directions for further exploration of the pharmacogenetic basis of this concerning multifactorial adverse event
First report of anti-TIF1Îł dermatomyositis in a patient with myelodysplastic syndrome.
Inflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1Îł) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1Îł dermatomyositis secondary to a myelodysplastic syndrome
Three-dimensional vascular ultrasound imaging in medium and large vessel vasculitis: our experience
Affectionless control: A parenting style associated with obesity and binge eating disorder in adulthood
- …